Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint)
10.1007/10.1007/s13139-018-00569-4
- Author:
Kyin MYINT
1
;
Tin Maung THEIN
;
Thiri Kyi PHYU
;
Win MAUNG
Author Information
1. PERFECT Myanmar Molecular Imaging and Therapy center (PERFECT MMITC), No (122/124), 15th street (Middle block), Ward 7, Lanmadaw Township, 11131 Yangon, Myanmar. kmnumed@gmail.com, drtinmaungthein.86@gmail.com, w.maung67@gmail.com
- Publication Type:Brief Communication
- Keywords:
Theranostics;
SPECT-CT;
PET-CT;
PSMA;
Lutetium-177;
Prostate cancer
- MeSH:
Castration;
Congresses as Topic;
Cost-Benefit Analysis;
Delivery of Health Care;
Humans;
Male;
Myanmar;
Neoplasm Metastasis;
Prostatic Neoplasms;
Theranostic Nanomedicine
- From:Korean Journal of Nuclear Medicine
2019;53(1):42-46
- CountryRepublic of Korea
- Language:English
-
Abstract:
Prostate cancer is third common malignancy in men of old age (average 65 years) in Myanmar. Currently, serum PSA and bone scan are the markers of choice. Because of the evidence-based, promising success of ⁶⁸Ga-PSMA PET-CT and 177Lu-PSMA theranostics in prostate cancer worldwide, (99m)Tc-PSMA SPECT-CT imaging and ¹⁷⁷Lu-PSMA therapy has launched as a stepping-stone of theranostics in Myanmar with the available facilities. Twelve cases of prostate cancer patients were imaged with 600 MBq of (99m)Tc-PSMA I+S SPECT-CT. Four metastatic castration resistant prostate cancer (MCRPC) patients with abnormal result were treated with ¹⁷⁷Lu-PSMA. The protocol consists of 6–8 GBq of ¹⁷⁷Lu-PSMA, three successive doses at interval of 4–6 weeks. Post-therapy SPECT-CT imaging was done. All treated patients were improved by free of bone pain, and fall/rise in serum PSA level. Two patients with extensive skeletal metastases succumbed to complications. The results are well documented and present at the multidisciplinary conferences for clinical awareness. Theranostics in prostate cancer with available facilities is an additional boon to our health care professionals to upgrade cancer management in Myanmar. This paper provides the technology with cost effectiveness and benefit to prostate cancer patients of Myanmar.
